Highlights Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 12/02/2026 am IST			5-day change	1st Jan Change
17.96 ^USD	-2.02%		-8.97%	-16.54%

11/02	Sarepta Therapeutics to announce fourth quarter and full-year 2025 financial results	RE
04/02	Sarepta Therapeutics announces clinical trial application approval for SRP-1005 in Huntington's disease	RE

Highlights

04/02	Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease	CI
27/01	Sector Update: Health Care Stocks Advance Late Afternoon	MT
27/01	Sector Update: Health Care Stocks Higher Monday Afternoon	MT
26/01	Sarepta Therapeutics, Inc. Announces Positive Topline Three-Year EMBARK Results Showing EleVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients	CI
12/01	Sarepta Preliminary Q4, 2025 Net Product Revenue Miss Estimates; Shares Fall	MT
07/01	Sarepta Therapeutics, Inc. Announces Submission of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease	CI
11/12	Sarepta Therapeutics Refinances $291 Million in Convertible Senior Notes Due 2027	MT
25/11	Sarepta Therapeutics, Inc. Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of Elevidys Gene Therapy for Non-Ambulant Individuals with Duchenne	CI
24/11	Sarepta Provides Progress Update for Srp-1003, Its Investigational Sirna Treatment for Myotonic Dystrophy Type 1	CI
15/11	Sector Update: Health Care Stocks Ease Late Afternoon	MT
15/11	Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information	CI
15/11	US FDA adds strongest warning to Sarepta's Elevidys after fatal liver injuries	RE
04/11	Sarepta Therapeutics Swings to Q3 Adjusted Loss, Revenue Falls; Shares Down Pre-Bell	MT
04/11	Sarepta Therapeutics Q3 revenue beats estimates on strong show from gene therapy ELEVIDYS	RE
04/11	Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Posts Q3 Adjusted Loss $0.13 per Share	MT
04/11	Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Reports Q3 Revenue $399.4M, vs. FactSet Est of $335.8M	MT
04/11	Sarepta Therapeutics Announces Completion of Its Confirmatory Study, ESSENCE	CI
04/11	Sarepta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
28/25/28	Sarepta Therapeutics to announce third quarter 2025 financial results	RE
14/25/14	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Inflation Data	MT
09/25/09	Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency	RE
09/25/09	Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency	RE
07/25/07	Sarepta Therapeutics Q2 Adjusted Earnings, Revenue Increase; Shares Up Pre-Bell	MT
07/25/07	Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Posts Q2 Adjusted EPS $2.02 per Share	MT
07/25/07	Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Reports Q2 Revenue $611.1M, vs. FactSet Est of $530.7M	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Highlights

Filters